Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21633076 | 0.83 | ADRB2 (0.46) | ADRB2MAPTGAACA2 | |
| SCHEMBL11093715 | 0.82 | ADRB2 (0.46) | ADRB2MAPTALDH1A1KDM4ENPSR1 | |
| SCHEMBL7871857 | 0.81 | MAPT (0.46) | MAPTALDH1A1KDM4EGAACA2 | |
| SCHEMBL14675666 | 0.81 | KDM4E (0.31) | ALDH1A1KDM4EGAAHPGDL3MBTL1 | |
| SCHEMBL21666326 | 0.80 | ADRB2 (0.39) | ADRB2 | |
| SCHEMBL2656380 | 0.79 | CYP1A2 (0.31) | ALDH1A1KDM4ENPSR1GAAHPGD | |
| SCHEMBL14675556 | 0.79 | XDH (0.45) | ADRB2MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL21633302 | 0.76 | ADRB2 (0.36) | ADRB2ALDH1A1KDM4ECA2 | |
| SCHEMBL29509959 | 0.76 | ADRB2 (0.36) | ADRB2ALDH1A1KDM4ECA2 | |
| SCHEMBL14685523 | 0.76 | SKP2 (0.36) | ADRB2MAPTHSD17B10GAACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739609-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-07-17 | — | — | EP | disclosed |
| EP-2739609-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-07-17 | — | — | EP | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| EP-2739609-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013017654-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | ADRB2 1070/4885MAPT 4342/4885ALDH1A1 1517/4885 |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | ADRB2 1070/4885MAPT 4342/4885ALDH1A1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.